Golish S Raymond, Groff Michael W, Araghi Ali, Inzana Jason A
Jupiter Medical Center, Palm Beach, FL, USA.
Brigham and Women's Hospital, Boston, MA, USA.
Global Spine J. 2020 May;10(3):332-345. doi: 10.1177/2192568219841046. Epub 2019 Jun 7.
Systematic review.
Superiority claims for medical devices are commonly derived from noninferiority trials, but interpretation of such claims can be challenging. This study aimed to () establish the prevalence of noninferiority and superiority designs among spinal device trials, () assess the frequency of post hoc superiority claims from noninferiority studies, and () critically evaluate the risk of bias in claims that could translate to misleading conclusions.
Study bias was assessed using the Cochrane Risk of Bias Tool. The risk of bias for the superiority claim was established based on post hoc hypothesis specification, analysis of the intention-to-treat population, post hoc modification of a priori primary outcomes, and sensitivity analyses.
Forty-one studies were identified from 1895 records. Nineteen (46%) were noninferiority trials. Fifteen more (37%) were noninferiority trials with a secondary superiority hypothesis specified a priori. Seven (17%) were superiority trials. Of the 34 noninferiority trials, 14 (41%) made superiority claims. A medium or high risk of bias was related to the superiority claim in 9 of those trials (64%), which was due to the analyzed population, lacking sensitivity analyses, claims not being robust during sensitivity analyses, post hoc hypotheses, or modified endpoints. Only 4 of the 14 (29%) noninferiority studies provided low bias in the superiority claim, compared with 3 of the 5 (60%) superiority trials.
Health care decision makers should carefully evaluate the risk of bias in each superiority claim and weigh their conclusions appropriately.
系统评价。
医疗器械的优越性声明通常源自非劣效性试验,但对此类声明的解读可能具有挑战性。本研究旨在:(1)确定脊柱器械试验中非劣效性和优越性设计的流行情况;(2)评估非劣效性研究中事后优越性声明的频率;(3)严格评估可能导致误导性结论的声明中的偏倚风险。
使用Cochrane偏倚风险工具评估研究偏倚。基于事后假设规范、意向性分析人群分析、先验主要结局的事后修改以及敏感性分析,确定优越性声明的偏倚风险。
从1895条记录中识别出41项研究。19项(46%)为非劣效性试验。另有15项(37%)为预先指定次要优越性假设的非劣效性试验。7项(17%)为优越性试验。在34项非劣效性试验中,14项(41%)提出了优越性声明。其中9项试验(64%)的优越性声明存在中度或高度偏倚风险,这是由于分析人群、缺乏敏感性分析、敏感性分析期间声明不稳健、事后假设或修改的终点所致。与5项优越性试验中的3项(60%)相比,14项非劣效性研究中只有4项(29%)在优越性声明方面提供了低偏倚。
医疗保健决策者应仔细评估每项优越性声明中的偏倚风险,并适当权衡其结论。